Selloff in this major biotech stock is "overdone," BTIG says

June 2, 2026 11:00 AM

A sharp pullback in a clinical-stage biotechnology company following its Phase 3 trial readout is unwarranted, BTIG analysts say.Shares in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found